X4 Pharmaceuticals, Inc
XFOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501697
In the last 90 days, X4 Pharmaceuticals, Inc insiders filed 0 open-market purchases and 3 sales; 89 institutions reported holding it in 13F filings for Q2 2026, worth $463.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by X4 Pharmaceuticals, Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 3 filings
- 3 insiders, $356.5K in total
- Insiders trading
- 3
- Net value
- −$356.5K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for X4 Pharmaceuticals, Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Volpone John | President | 265,305 | Aug 13, 2026 | 2 |
| Craig Adam R | Executive Chairman | 328,651 | Aug 13, 2026 | 3 |
| Kirske David | Chief Financial Officer | 167,750 | Jul 1, 2026 | 3 |
| Gold Kelly | Director | – | Jul 1, 2026 | 1 |
| Bridger Gary | Director | 4,722 | Jan 7, 2026 | 1 |
| Wyzga Michael S | Director | 5,555 | Jan 5, 2026 | 1 |
| Stewart Murray | Director | 7,883 | Jan 5, 2026 | 1 |
| de Craecker Francoise | Director | 4,722 | Jan 5, 2026 | 1 |
| Thoren Natasha Fay | Chief Legal Officer | 9,462 | Jul 3, 2025 | 0 |
| McGirr David W J | Director | 4,722 | Jun 10, 2025 | 0 |
| Woods Keith | Director | 6,000 | Jun 10, 2025 | 0 |
| Baldry Mark | Chief Commercial Officer | 25,337 | Jun 3, 2025 | 0 |
| Mostafa Adam S. | Chief Financial Officer | 850,000 | Feb 14, 2025 | 0 |
| Ragan Paula | President and CEO | 3,337,386 | Feb 14, 2025 | 0 |
| Arbet-Engels Christophe | Chief Medical Officer | 864,207 | Feb 14, 2025 | 0 |
| DiBiase Mary | Chief Operating Officer | 1,140,980 | Feb 14, 2025 | 0 |
| Taveras Arthur | Chief Scientific Officer | 388,026 | Oct 8, 2024 | 0 |
| Lawton Alison Frances | Director | 96,667 | Jun 11, 2024 | 0 |
| Aliski William | Director | 96,667 | Jun 11, 2024 | 0 |
| Meisner Derek M | Chief Legal Officer | 145,155 | Aug 19, 2022 | 0 |
| Cadavid Diego | Chief Medical Officer | 104,107 | Mar 1, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2024 (view filing) | Feb 12 | Same day | Mostafa Adam S.Chief Financial Officer | SSale | −27.7K | $1.01 | −$28.0K | −34.6%52.5K after | |
| Feb 12, 2024 (view filing) | Feb 12 | Same day | Ragan PaulaPresident and CEO | SSale | −21.7K | $1.01 | −$21.9K | −2.6%814.7K after | |
| Feb 12, 2024 (view filing) | Feb 12 | Same day | Taveras ArthurChief Scientific Officer | SSale | −787 | $1.01 | −$794.87 | −0.3%248.5K after | |
| Feb 12, 2024 (view filing) | Feb 12 | Same day | DiBiase MaryChief Operating Officer | SSale | −3.68K | $1.01 | −$3.72K | −1.2%307.2K after | |
| Mar 11, 2024 (view filing) | Mar 11 | Same day | DiBiase MaryChief Operating Officer | SSale | −15.4K | $0.88 | −$13.6K | −5.0%291.8K after | |
| Mar 11, 2024 (view filing) | Mar 11 | Same day | Mostafa Adam S.Chief Financial Officer | SSale | −52.5K | $0.88 | −$46.2K | −100.0%0 after | |
| Mar 11, 2024 (view filing) | Mar 11 | Same day | Ragan PaulaPresident and CEO | SSale | −49.7K | $0.88 | −$43.7K | −6.1%765.1K after | |
| Mar 11, 2024 (view filing) | Mar 11 | Same day | Taveras ArthurChief Scientific Officer | SSale | −14.2K | $0.88 | −$12.5K | −5.7%234.3K after | |
| Sep 11, 2024 (view filing) | Sep 9 | 2 days | DiBiase MaryChief Operating Officer | SSale | −2.64K | $0.66 | −$1.74K | −0.9%289.1K after | |
| Oct 8, 2024 (view filing) | Oct 7 | 1 day | Taveras ArthurChief Scientific Officer | SSale | −76.9K | $0.56 | −$43.1K | −16.5%388.0K after | |
| Oct 8, 2024 (view filing) | Oct 7 | 1 day | DiBiase MaryChief Operating Officer | SSale | −67.7K | $0.57 | −$38.6K | −13.0%452.1K after | |
| Oct 8, 2024 (view filing) | Oct 7 | 1 day | Ragan PaulaPresident and CEO | SSale | −239.4K | $0.55 | −$131.7K | −18.5%1.06M after | |
| Oct 8, 2024 (view filing) | Oct 7 | 1 day | Baldry MarkChief Commercial Officer | SSale | −11.1K | $0.58 | −$6.45K | −18.7%48.5K after | |
| Oct 8, 2024 (view filing) | Oct 7 | 1 day | Mostafa Adam S.Chief Financial Officer | SSale | −230.6K | $0.55 | −$126.9K | −100.0%0 after | |
| Oct 16, 2024 (view filing) | Oct 15 | 1 day | Ragan PaulaPresident and CEO | SSale | −31.9K | $0.56 | −$17.9K | −3.0%1.03M after | |
| Nov 19, 2024 (view filing)4:31 PM ET | Nov 15 | 4 days | Ragan PaulaPresident and CEO | SSale | −31.9K | $0.3945 | −$12.6K | −3.1%993.9K after | |
| Jan 27, 2025 (view filing)6:15 PM ET | Jan 24 | 3 days | Arbet-Engels ChristopheChief Medical Officer | SSale | −11.6K | $0.4546 | −$5.28K | −45.0%14.2K after | |
| Jan 27, 2025 (view filing)6:15 PM ET | Jan 24 | 3 days | DiBiase MaryChief Operating Officer | SSale | −22.3K | $0.4535 | −$10.1K | −4.3%491.0K after | |
| Jan 27, 2025 (view filing)6:15 PM ET | Jan 24 | 3 days | Baldry MarkChief Commercial Officer | SSale | −29.2K | $0.4541 | −$13.2K | −23.7%94.1K after | |
| Jan 27, 2025 (view filing)6:15 PM ET | Jan 24 | 3 days | Mostafa Adam S.Chief Financial Officer | SSale | −74.8K | $0.454 | −$33.9K | −100.0%0 after | |
| Jan 27, 2025 (view filing)6:15 PM ET | Jan 24 | 3 days | Ragan PaulaPresident and CEO | SSale | −76.5K | $0.454 | −$34.7K | −6.6%1.09M after | |
| Feb 14, 2025 (view filing)4:08 PM ET | May 17-Nov 15, 2024 | 273 daysLate | Baldry MarkChief Commercial Officer | PPurchase | +35.0K | $0.5493 | +$19.3K | +37.2%129.2K after | 2 lots |
| Oct 27, 2025 (view filing) | Oct 23 | 4 days | Craig Adam RExecutive Chairman | PPurchase | +86.2K | $2.90 | +$250.0K | +29.7%376.1K after | |
| May 13, 2026 (view filing) | May 12 | 1 day | Kirske DavidChief Financial Officer | SSale | −17.0K | $4.29 | −$72.8K | −8.8%176.3K after | |
| Jul 1, 2026 (view filing)4:23 PM ET | Jun 30 | 1 day | Kirske DavidChief Financial Officer | SSale | −8.54K | $4.26 | −$36.4K | −4.8%167.8K after | |
| Aug 13, 2026 (view filing)4:10 PM ET | Aug 12 | 1 day | Craig Adam RExecutive Chairman | SSale | −47.4K | $4.44 | −$210.8K | −12.6%328.7K after | |
| Aug 13, 2026 (view filing)4:13 PM ET | Aug 12 | 1 day | Volpone JohnPresident | SSale | −24.6K | $4.44 | −$109.2K | −8.5%265.3K after |